Bryce Beverlin II, Ph.D

Founder and CEO at Quench Medical

Bryce Beverlin II, Ph.D. is Founder and CEO of Quench Medical with over a decade of R&D experience in post-doctoral commercialization training at the University of Minnesota Earl Bakken Medical Devices Center and as a physics Ph.D. in a biomedical engineering lab. He has developed technologies for Boston Scientific, Teijin Pharma, and the University of Minnesota and has clinical study experience from working at Guidant Corp.

Dr. Beverlin is leading Quench Medical in developing an approved chemotherapeutic medication being reformulated for inhalation to treat lung cancer by directly targeting lung tumors and minimizing systemic toxicity. The high efficiency targeted respiratory drug delivery platform technology, originally developed at Virginia Commonwealth University in the labs of Drs. Hindle and Longest, will be extended to address further traditional inhaler markets of lung diseases as well (asthma, COPD, cystic fibrosis).

Quench Medical received a $225k SBIR grant from the National Institutes of Health in March 2018.

Bryce_Beverlin_II_Quench_Medical_Biotech_Pharma_Summit_IRDD_New_York_Inhalation_Respiratory_Profile

Topic to be announced (Developing new formulations of inhaler medications)

 

 

Other Speakers from the IRDD Summit 2020

Aernout van Haarst

Director, Scientific Affairs at Celerion

Diana Fernandes

Inhaled Biopharmaceutical Development Scientist at Hovione

Dino Farina

Founder and CEO at Proveris Scientific